HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lexon

This article was originally published in The Gray Sheet

Executive Summary

Diagnostics developer raises $30 mil. from Swartz Private Equity, LLC, to be drawn by Lexon as needed over the next three years. Tulsa, Oklahoma-based Lexon, which owns the exclusive worldwide rights to the Ebaf Assay blood test to screen for colon cancer and the Telomerase Assay blood test to screen for lung cancer, will use the funds for "ongoing product development and initiation of FDA clinical trials," the firm states in an Aug. 21 release. Current development efforts "are focused on expanding the battery of monoclonal antibodies for each test, producing prototype blood screening test kits, performing multiple blood tests on known cancer patients, and statistically evaluating test results for presentation to the FDA," Lexon reports

You may also be interested in...



EU Call For Coronavirus Projects Sparks Big Pharma Interest

Europe’s Innovative Medicines Initiative is calling for R&D projects aimed at tackling the spread of COVID-19, saying that collaborative ventures have the potential to accelerate the development of therapeutics and diagnostics to tackle this and future coronavirus outbreaks.

AAM Slams Medicare Delays For First Generics

The AAM has cited multiple reasons for the failure of Medicare Part D to get new generics to its patients, forcing up their costs. The association has offered a list of suggestions to “ensure that first generics are covered at launch, with lower cost-sharing.”

FDA Recommends Further Limiting Use Of Laparoscopic Power Morcellation

The US FDA is updating its labeling guidance on laparoscopic power morcellation to reflect new evidence showing the treatment may pose a higher cancer risk in older women, as well as to add discussion of containment systems.

UsernamePublicRestriction

Register

MT013785

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel